Clinical review report: Erenumab (Aimovig) (Novartis pharmaceuticals Canada Inc.) indication: for prevention of migraine in patients who have had at least four migraine days monthly
The objective of this review is to perform a systematic review of the beneficial and harmful effects of erenumab for the prevention of migraine in adults who have at least four migraine days per month
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
September 2020, 2020
|
| Edition: | Version: Final (with redactions) |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of erenumab for the prevention of migraine in adults who have at least four migraine days per month |
|---|---|
| Physical Description: | 1 PDF file (163 pages) |